179 related articles for article (PubMed ID: 8683246)
1. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.
Sanchez E; Chacon I; Plaza MM; Muñoz E; Cruz MA; Martinez B; Lopez L; Martinez-Montero JC; Orradre JL; Saez AI; Garcia JF; Piris MA
J Clin Oncol; 1998 May; 16(5):1931-9. PubMed ID: 9586912
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
4. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
5. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
[TBL] [Abstract][Full Text] [Related]
7. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.
Maartense E; Kramer MH; le Cessie S; Kluin-Nelemans JC; Kluin PM; Snijder S; Noordijk EM
Leuk Lymphoma; 2004 Jan; 45(1):101-7. PubMed ID: 15061204
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
10. Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.
Pervez S; Nasir MI; Moatter T; Ahsan A; Haq A; Siddiqui T
J Cancer Res Ther; 2009; 5(4):254-62. PubMed ID: 20160358
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis-regulating proteins and prognosis in diffuse large B cell non-Hodgkin's lymphomas.
Pagnano KB; Silva MD; Vassallo J; Aranha FJ; Saad ST
Acta Haematol; 2002; 107(1):29-34. PubMed ID: 11818669
[TBL] [Abstract][Full Text] [Related]
13. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
[TBL] [Abstract][Full Text] [Related]
14. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
[TBL] [Abstract][Full Text] [Related]
15. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
16. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
17. An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
Huebner-Chan D; Fernandes B; Yang G; Lim MS
Mod Pathol; 2001 Oct; 14(10):1000-7. PubMed ID: 11598170
[TBL] [Abstract][Full Text] [Related]
18. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.
Camacho FI; Mollejo M; Mateo MS; Algara P; Navas C; Hernández JM; Santoja C; Solé F; Sánchez-Beato M; Piris MA
Am J Surg Pathol; 2001 Oct; 25(10):1268-76. PubMed ID: 11688461
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous large B-cell lymphoma: the relation between morphology, clinical presentation, immunohistochemical markers, and survival.
Fernández-Vázquez A; Rodríguez-Peralto JL; Martínez MA; Platón EM; Algara P; Camacho FI; López-Ríos F; Zarco C; Sánchez-Yus E; Fresno MF; Barthe L; Aliaga A; Fraga M; Forteza J; Oliva H; Piris MA
Am J Surg Pathol; 2001 Mar; 25(3):307-15. PubMed ID: 11224600
[TBL] [Abstract][Full Text] [Related]
20. [Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].
Ding X; Hou SL; Li YQ; Li X; Li L; Lian K; Wang GG; Wu XB; Zhang ZH; Liu H; Wang YQ; Zhang QH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1504-1514. PubMed ID: 31607305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
